Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Black Diamond Therapeutics

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-189

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            MasterKey-01, the Company’s first-in-human Phase 1/2 clinical trial for its lead product candidate BDTX-189, will be presented as a poster presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-189

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Versant Ventures

            Deal Size: $201.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 29, 2020

            Details:

            Black Diamond was the first company to emerge from Ridgeline, Versant’s Discovery Engine based in the Basel Technology Park.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BDTX-189

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: J.P. Morgan Securities

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 03, 2020

            Details:

            The company’s plans for the IPO cash include financing Phase 1/2 tests of BDTX-189 and advancing preclinical development of its glioblastoma drug.